Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Monotherapy in Relapsed/Refractory Autoimmune Hemolytic Anemia or Evans Syndrome
ChiCTR2100045594Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orelabrutinib in autoimmune haemolytic anaemia (AIHA) and Evans syndrome, sponsored by Tianjin Medical University General Hospital. Primary endpoints: Complete blood count, Liver function and 3 more. Started Apr 2021; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
autoimmune haemolytic anaemia (AIHA)Evans syndrome
Beyond the preview
Go deeper on ChiCTR2100045594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045594.